{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:50:36Z","timestamp":1782737436806,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate why, when and in which patterns decisions about changes in systemic medications were made in a cohort of JIA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JIA patients starting first-line systemic therapy were prospectively followed in a Dutch tertiary paediatric rheumatology centre. Treatment lines were constructed for the included systemic therapies (systemic corticosteroids, conventional and biological DMARDs (cDMARDs and bDMARDs)). Each change in systemic medication and its reason was registered. Main outcomes were frequencies and timing of change reasons, across treatment lines. A Sankey diagram was used to visualize flows between change reasons over treatment lines, cumulative incidences Fine-Gray models to illustrate the frequencies of the change reasons over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five hundred fifty-one patients were included of which 67.9% were female and oligoarticular JIA was the most common JIA diagnosis (41.9%). Thousand four hundred twenty-two different systemic drug treatment lines were observed, with a median number of 2 (IQR 1\u20133) treatment lines per patient. MTX was predominantly used as first treatment line (89.1%), while bDMARDs were mostly used as next treatment line (53.3%). JIA medication was mostly changed because of inefficacy (42.9%) in the first treatment line vs remission in the second treatment line (46.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JIA medication is mostly changed because of inefficacy in the first treatment line (predominantly MTX) vs remission in the second treatment line (roughly half on bDMARDs). This indicates that bDMARDs may be a more effective treatment than MTX in part of the JIA population, advocating reconsideration of current JIA treatment guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag296","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:35:11Z","timestamp":1781004911000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in systemic medication in children and adolescents with JIA: why, when and which patterns"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-1313","authenticated-orcid":false,"given":"Merel","family":"Boer-de Boer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7281-1304","authenticated-orcid":false,"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Department of Pediatric Rheumatology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Faculty of Medicine, Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-7779","authenticated-orcid":false,"given":"Toine C G","family":"Egberts","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Faculty of Science, Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-3501","authenticated-orcid":false,"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, Faculty of Science, Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2759-2822","authenticated-orcid":false,"given":"Joost F","family":"Swart","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Department of Pediatric Rheumatology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Faculty of Medicine, Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026062908415444700_keag296-B1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2026062908415444700_keag296-B2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"2026062908415444700_keag296-B3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00132-018-3645-1","article-title":"[Therapeutic options in juvenile idiopathic arthritis: part 1: nonsurgical treatment]","volume":"47","author":"Haas","year":"2018","journal-title":"Orthopade"},{"key":"2026062908415444700_keag296-B4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/kez291","article-title":"Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis","volume":"59","author":"Gr\u00f6nlund","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026062908415444700_keag296-B5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","article-title":"Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026062908415444700_keag296-B6","doi-asserted-by":"crossref","first-page":"Si170","DOI":"10.1093\/rheumatology\/keac299","article-title":"Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis","volume":"62","author":"Kip","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026062908415444700_keag296-B7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","article-title":"Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept","volume":"14","author":"Verazza","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062908415444700_keag296-B8","author":"Welsing","year":"2011"},{"key":"2026062908415444700_keag296-B9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/acr.22903","article-title":"Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis","volume":"68","author":"Luca","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026062908415444700_keag296-B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12969-022-00748-w","article-title":"Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis","volume":"20","author":"Tarkiainen","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062908415444700_keag296-B11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/art.43401","article-title":"Effect of time to start of biologic therapy on treatment response in childhood arthritis: results from the UCAN CAN-DU study","volume":"78","author":"de Jonge","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026062908415444700_keag296-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12969-022-00682-x","article-title":"Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study","volume":"20","author":"Grazziotin","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062908415444700_keag296-B13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","article-title":"Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients","volume":"65","author":"Romano","year":"2014","journal-title":"Reumatismo"},{"key":"2026062908415444700_keag296-B14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis","volume":"68","author":"Tynj\u00e4l\u00e4","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026062908415444700_keag296-B15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/cancers16040709","article-title":"Reasons for treatment discontinuation and their effect on outcomes of immunotherapy in southwest finland: a retrospective, real-world cohort study","volume":"16","author":"Virtanen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026062908415444700_keag296-B16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-019-03601-5","article-title":"Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myeloma","volume":"98","author":"Sen\u00edn","year":"2019","journal-title":"Ann Hematol"},{"key":"2026062908415444700_keag296-B17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7224\/1537-2073.2018-068","article-title":"Exploring adherence to first-line and second-line immunotherapies in multiple sclerosis: an interview study","volume":"22","author":"Pust","year":"2020","journal-title":"Int J MS Care"},{"key":"2026062908415444700_keag296-B18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/PPA.S93219","article-title":"Identify practice gaps in medication education through surveys to patients and physicians","volume":"9","author":"Yi","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026062908415444700_keag296-B19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10067-010-1444-0","article-title":"What does it mean to grow up with juvenile idiopathic arthritis? A qualitative study on the perspectives of patients","volume":"30","author":"Eyckmans","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2026062908415444700_keag296-B20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/annrheumdis-2017-212104","article-title":"Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis","volume":"77","author":"Swart","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026062908415444700_keag296-B21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"2026062908415444700_keag296-B22","author":"Nederlandse Vereniging voor Kindergeneeskunde","year":"2025"},{"key":"2026062908415444700_keag296-B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"2026062908415444700_keag296-B24","author":"Sjoberg","year":"2024"},{"key":"2026062908415444700_keag296-B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the cox model","author":"Therneau","year":"2000"},{"key":"2026062908415444700_keag296-B26","author":"Allaire","year":"2017"},{"key":"2026062908415444700_keag296-B27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.55563\/clinexprheumatol\/rxidz4","article-title":"Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis","volume":"39","author":"Bava","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026062908415444700_keag296-B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12969-022-00769-5","article-title":"Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors","volume":"20","author":"Gieling","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062908415444700_keag296-B29","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.3390\/jcm11195674","article-title":"Treat to target (drug-free) inactive disease in JIA: to what extent is this possible?","volume":"11","author":"Ramanan","year":"2022","journal-title":"J Clin Med"},{"key":"2026062908415444700_keag296-B30","doi-asserted-by":"crossref","first-page":"O8","DOI":"10.1186\/1546-0096-12-S1-O8","article-title":"A multinational study of the epidemiology, treatment and outcome of childhood arthritis (EPOCA study): preliminary data from 6,940 patients","volume":"12","author":"Consolaro","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062908415444700_keag296-B31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12969-025-01173-5","article-title":"Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice","volume":"23","author":"Lamers","year":"2025","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag296\/68508361\/keag296.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/6\/keag296\/68508361\/keag296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/6\/keag296\/68508361\/keag296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:41:59Z","timestamp":1782736919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag296\/8705548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag296","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"keag296"}}